Products classification
ABOUT US
Email:
sales@ruixibiotech.com
Tel.:
02988811435
Home > products > apis> gpcr-g-protein
Catalog name Description price
R-R-4197 AZD-4818 CAS No.1003566-93-5 AZD-4818/CAS No.1003566-93-5 is a potent antagonist of chemokine CCR1. AZD-4818 can be used for researching chronic obstructive pulmonary disease (COPD) . price>
R-R-4198 AZD2423 CAS No.1229603-37-5 AZD2423/CAS No.1229603-37-5 is a potent, selective, orally bioavailable, and non-competitive CCR2 chemokine receptor negative allosteric modulator. AZD2423 has an IC50 of 1.2 nM for CCR2 Ca2+ flux . price>
R-R-4199 CCR4-351 CAS No.2174938-70-4 CCR4-351/CAS No.2174938-70-4 is an orally active, potent and selective CCR4 antagonist. CCR4-351, featuring a novel piperidinyl-azetidine motif, has IC50s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 has antitumor activity. price>
R-R-4200 AZD-5672 CAS No.780750-65-4 AZD-5672/CAS No.780750-65-4 is an orally active, potent, and selective CCR5 antagonist (IC50=0.32 nM). AZD-5672 shows moderate activity against the hERG ion channel (binding IC50=7.3 μM). AZD5672 is a substrate of human P-gp, and inhibits P-gp-mediated digoxin transport (IC50=32 μM). AZD-5672 can be used for the research of rheumatoid arthritis. price>
R-R-4201 CCR8 antagonist 2 CAS No.2756350-98-6 CCR8 antagonist 2/CAS No.2756350-98-6 is a potent antagonist of CCR8. CCR8 (C-C Motif Chemokine Receptor 8) is predominantly expressed on Treg cells and Th2 cells, but not on Th1 cells. CCR8 antagonist 2 inhibits CCR8 activity, which may be used in the research of diseases mediated by CCR8, such as cancer, and/or neuropathic pain (extracted from patent WO2022000443A1, compound 220). price>
R-R-4202 IPG7236 CAS No.2756350-91-9 IPG7236/CAS No.2756350-91-9 is a selective CCR8 antagonist. IPG7236 exhibits significant tumor suppression in a mouse xenograft model of human breast cancer. IPG7236 can be used in cancer research. price>
R-R-4203 MLN3126 CAS No.628300-71-0 MLN3126/CAS No.628300-71-0 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC50 value of 6.3 nM for calcium influx. price>
R-R-4204 CKLF1-C19 CAS No.960358-79-6 CKLF1-C19/CAS No.960358-79-6 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4. price>
R-R-4205 C-021 dihydrochloride CAS No.1784252-84-1 C-021 dihydrochloride/CAS No.1784252-84-1 is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 dihydrochloride effectively prevents human CCL22-derived [35S]GTPγS from binding to the receptor with an IC50 of 18 nM. price>
R-R-4206 Vercirnon sodium CAS No.886214-18-2 Vercirnon (GSK1605786A) sodium/CAS No.886214-18-2 is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 µM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively. price>